


TAP INTO A NETWORK OF PAEDIATRIC EXPERTS ACROSS EUROPE




Being able to efficiently consult a diverse and multidisciplinary network of experts, tapping into their up-to-date and in-depth knowledge can provide value at any stage of paediatric drug development.

- Find the **right profiles** tailored to each situation and local context
- **Streamline consultations** through pre-existing signed contracts for each expert
- **Hear the voice of children, young people and families**
- Improve **recruitment and retention**

At conect4children Stichting (c4c-S), our Expert Advice enables **scientifically sound, innovative, and feasible trials** to be planned **faster**. Input from children, young people and families make studies more relevant, ethical and feasible. Advice from established experts can help in designing, adapting and improving study protocols as well as boosting recruitment and retention.



The **Single Point of Contact (SPoC)** acts as the gateway to the c4c-S network, providing an efficient and user-friendly way of engaging c4c-S's experts with a single request.



400+ EXPERTS IN 25+ MEDICAL SPECIALTIES

PUBLIC PATIENT INVOLVEMENT (PPI)

- Advice from:
- Parent/carers...
 - Patient organisation representatives
 - Patients
 - Young people

CLINICAL AREAS

- Cardiology/respiratory/neonatology...
- Infectious diseases
- Oncology
- Rare diseases
- Cell and gene therapies

INNOVATIVE METHODOLOGY

- Extrapolation
- Innovative statistical approaches
- Modelling and simulation
- Study design

Please visit our website to see the full list: https://conect4children.org/sfas_experts/



Stay informed about c4c-S:
c4c.spoc@conect4children.eu

Certain information in this communication contains forward-looking statements, including statements related to the expected scope and timing of launch of services, as well as the number of countries and/or sites at time of launch of related services based upon what we believe are reasonable assumptions.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777389.

The Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

This publication reflects the authors' views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.

